world-biomarkers-pharma-biotech-2017-posters

Volume10, Issue 12 (Suppl)

J Proteomics Bioinform, an open access journal

ISSN: 0974-276X

Page 115

conferenceseries

.com

World Biomarkers & Pharma Biotech 2017

December 07-09, 2017

December 07-09, 2017 | Madrid, Spain

International Conference on

PHARMACEUTICAL BIOTECHNOLOGY

WORLD BIOMARKERS CONGRESS

JOINT EVENT ON

J Proteomics Bioinform 2017, 10:12(Suppl)

DOI: 10.4172/0974-276X-C1-110

Screening of proteins targeting circulating miRNAs for improved diagnosis of multiple myeloma using

computational methods

Sameer Srivastava, Shradha Suyal, Manish Pratap Singh

and

B S Yadav

Motilal Nehru National Institute of Technology, India

ultiple myeloma is a B-cell malignancy, which is characterized by the expansion of clonal plasma cells in the bone marrow,

thereby leading to abnormal accumulation of monoclonal antibodies in circulation. The condition arises from an asymptomatic

multiplication of plasma cells, called MGUS (Monoclonal gammopathy of undetermined significance) which eventually progresses

to Myeloma. Till date, there are no explicit assays that can discriminate between the premalignant and malignant stages. Circulating

miRNAs are deregulated in MM cells and bone marrow. Their differential expression profiles in various body fluids can be quantified

and used for the diagnosis of MM. The study focuses on identification of such a protein which would show exclusive affinity for a

selected panel of circulating miRNAs reported to be deregulated in MM. A few human RNA binding proteins were selected based on

their RNA binding domains and their interacting probabilities with the panel of miRNAs. The 3D structure of miRNAs and proteins

were modelled and validated. Molecular Docking was performed for determining the protein-miRNA interaction using AutoDock

Vina. Out of the selected proteins, DKC1 showed good binding affinity values of -17.4 kcal/mol with miRNA-720, -16 kcal/mol with

miRNA-1246 and -16.9 kcal/mol with miRNA-1308. It also showed some significant hydrogen bonding. miRNA 26 was used as an

internal control for docking as it is a circulating miRNA without any significant relation to MM. This protein-miRNA interaction

could be used as an economical and reliable ELISA based method for the improved diagnosis of Multiple Myeloma patients.